Stock Price
33.08
Daily Change
2.96%
Yearly
-46.02%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Astellas Pharma 1,928.50 60.00 3.21% 16.07%
Agios Pharmaceuticals 33.14 1.19 3.72% -27.44%
Alnylam Pharmaceuticals 148.50 0.50 0.34% -10.74%
Arena Pharmaceuticals 92.65 0.18 0.19% 15.09%
Arrowhead Research 57.81 0.23 0.40% -28.40%
BioCryst Pharmaceuticals 15.48 -0.67 -4.15% 75.91%
Bluebird Bio 8.73 0.21 2.46% -82.72%
BioMarin Pharmaceutical 90.22 2.06 2.34% 8.74%
Dicerna Pharmaceuticals 38.22 0.22 0.58% 71.54%
Esperion Therapeutics 3.93 -0.20 -4.84% -84.62%
Exelixis 18.12 0.35 1.97% -23.62%
GW Pharmaceuticals 218.96 0 0% 108.53%
Halozyme Therapeutics 35.56 0.05 0.14% -25.03%
Intercept Pharmaceuticals 17.76 1.31 7.96% -35.30%
Moderna Inc 204.73 -5.44 -2.59% 57.91%
Mirati Therapeutics 124.31 5.57 4.69% -42.04%
Neurocrine Biosciences 78.36 -0.86 -1.09% -27.24%
Nektar Therapeutics 12.10 0.10 0.83% -28.74%
Novartis 82.32 -0.18 -0.22% -3.49%
Omeros 5.77 -0.03 -0.52% -68.05%
Pfizer 54.95 -0.59 -1.06% 49.73%
PTC Therapeutics 43.75 1.52 3.60% -36.12%
Ultragenyx Pharmaceutical 72.05 2.16 3.09% -47.78%
Regeneron Pharmaceuticals 615.24 -0.87 -0.14% 18.79%
Roche Holding 365.00 2.85 0.79% 15.27%
Sarepta Therapeutics 71.10 -1.29 -1.78% -21.28%
Vertex Pharmaceuticals 234.06 7.48 3.30% 3.77%


Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).